These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 31292525)
21. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study. Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636 [TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies. Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796 [TBL] [Abstract][Full Text] [Related]
23. Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma. Takashima Y; Kawaguchi A; Fukai J; Iwadate Y; Kajiwara K; Hondoh H; Yamanaka R PLoS One; 2021; 16(6):e0251272. PubMed ID: 34166375 [TBL] [Abstract][Full Text] [Related]
24. Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. Zhang X; Yin X; Zhang H; Sun G; Yang Y; Chen J; Zhu X; Zhao P; Zhao J; Liu J; Chen N; Wang J; Shen P; Zeng H BMC Cancer; 2019 Apr; 19(1):360. PubMed ID: 30992011 [TBL] [Abstract][Full Text] [Related]
25. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma. Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073 [TBL] [Abstract][Full Text] [Related]
26. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467 [TBL] [Abstract][Full Text] [Related]
27. Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112 [TBL] [Abstract][Full Text] [Related]
28. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046 [TBL] [Abstract][Full Text] [Related]
29. GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL. Takashima Y; Hamano M; Fukai J; Iwadate Y; Kajiwara K; Kobayashi T; Hondoh H; Yamanaka R Sci Rep; 2020 May; 10(1):8435. PubMed ID: 32439996 [TBL] [Abstract][Full Text] [Related]
30. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. Yeong J; Lim JCT; Lee B; Li H; Ong CCH; Thike AA; Yeap WH; Yang Y; Lim AYH; Tay TKY; Liu J; Wong SC; Chen J; Lim EH; Iqbal J; Dent R; Newell EW; Tan PH J Immunother Cancer; 2019 Feb; 7(1):34. PubMed ID: 30728081 [TBL] [Abstract][Full Text] [Related]
31. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Berghoff AS; Ricken G; Widhalm G; Rajky O; Hainfellner JA; Birner P; Raderer M; Preusser M Clin Neuropathol; 2014; 33(1):42-9. PubMed ID: 24359606 [TBL] [Abstract][Full Text] [Related]
32. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1. Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721 [TBL] [Abstract][Full Text] [Related]
33. Molecular Mechanisms of PD-1 and PD-L1 Activity on a Pan-Cancer Basis: A Bioinformatic Exploratory Study. Kannan S; O'Connor GM; Bakker EY Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34067485 [TBL] [Abstract][Full Text] [Related]
34. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910 [TBL] [Abstract][Full Text] [Related]
35. New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL). Gomes Candido Reis D; Levy D; Lage LAPC; Culler HF; Rocha V; Bydlowski SP; Nogueira Zerbini MC; Pereira J Brain Behav; 2021 Apr; 11(4):e02061. PubMed ID: 33591648 [TBL] [Abstract][Full Text] [Related]
36. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer. Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572 [TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression in small cell neuroendocrine carcinomas. Schultheis AM; Scheel AH; Ozretić L; George J; Thomas RK; Hagemann T; Zander T; Wolf J; Buettner R Eur J Cancer; 2015 Feb; 51(3):421-6. PubMed ID: 25582496 [TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic correlates of Sethi TK; Kovach AE; Grover NS; Huang LC; Lee LA; Rubinstein SM; Wang Y; Morgan DS; Greer JP; Park SI; Ann Thompson-Arildsen M; Yenamandra A; Vnencak-Jones CL; Reddy NM Leuk Lymphoma; 2019 Dec; 60(12):2880-2889. PubMed ID: 31184237 [TBL] [Abstract][Full Text] [Related]
40. Identification of PDCD1 and PDCD1LG2 as Prognostic Biomarkers and Associated with Immune Infiltration in Hepatocellular Carcinoma. Li W; Mei M; Liu T; Zhang S; Wang Z; Suo Y; Wang S; Liu Y; Zhang N; Lu W Int J Gen Med; 2022; 15():437-449. PubMed ID: 35046705 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]